A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin), Multicenter Study, To Evaluate The Safety And Efficacy In 2 Doses Of Apixaban In Comparison To Warfarin, Administered For 12 Weeks In Subjects With NVAF.
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2013
At a glance
- Drugs Apixaban; Warfarin
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 09 Oct 2009 Actual end date (Sep 2009), actual number of patients (222) added as reported by ClinicalTrials.gov.
- 09 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.